受体酪氨酸激酶ROS在肿瘤中作用的研究进展  

Research Progress on the Roles of Receptor Tyrosine Kinase ROS in Tumor

作　　者：谢蒙蒙 李莹[1] 文周[1] 吴晓波[2] 程泽能[1] 

机构地区：[1]中南大学药学院,湖南长沙410013 [2]中南大学湘雅三医院普外科,湖南长沙410013

出　　处：《肿瘤药学》2016年第3期166-172,共7页Anti-Tumor Pharmacy

摘　　要：受体酪氨酸激酶(RTKs)是最大的一类酶联受体,它既是受体,又是酶,能够与配体结合,并将靶蛋白的酪氨酸残基磷酸化。RTKs介导的信号转导与肿瘤的发生发展密切相关,因此阻断RTKs可破坏肿瘤细胞的信号传递,从而达到抗肿瘤的目的。ROS在30多年前被发现,是UR2病毒的致癌基因的产物。研究发现ROS可能引起酪氨酸激酶活性的激活。本文综述了ROS在基因调控中发挥的作用,在疾病中的表达以及细胞增殖和细胞存活过程中介导的信号转导等,为肿瘤的治疗提供新的干预靶点和治疗思路。As the largest category of enzyme-linked receptors, receptor tyrosine kinases （RTKs） can phosphorylate the tyrosine residues of target protein, through working both as a kind of receptor and an enzyme. The mediated signal transduction of RTKs is closely related to the tumor development, so that the tumor cells can be damaged by blocking tyrosine kinase signaling to achieve the purpose of antitumor. Reactive oxygen species （ROS） was found in UR2 carcinogenic product more than 30 years ago. It was found that it may cause the activation of tyrosine kinase activity. This paper gives an overview of the role of ROS in gene regulation, expression in the diseases and ROS-mediated signal transduction in the process of cell proliferation and cell survival signaling. This review may offer new intervention targets and arouse thoughts for the treatment of cancers.

关 键 词：受体酪氨酸激酶 ROS 肿瘤 信号转导 

分 类 号：R966[医药卫生—药理学]